Posted by Michael Wonder on 26 Apr 2018
Enzychem Lifesciences' fast track designation for chemo-radiation induced oral mucositis had been granted by the FDA
24 April 2018 - On 14 March, the U.S. FDA has granted Enzychem Lifesciences fast track designation of clinical study of EC-18, a synthetic palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (mosedipimod), to facilitate the research of safety and efficacy in managing chemo-radiation induced oral mucositis.
Enzychem Lifesciences' EC-18 is a candidate compound for a new drug with immunomodulation function.
Enzychem Lifesciences successfully completed Phase I clinical trials in Korea and in the United States. Currently, Enzychem is conducting Phase II clinical trials on the indications of Chemotherapy Induced Neutropenia (CIN) and CRIOM. EC-18 was granted Fast Track Designation as it proved potential on oral mucositis treatment, the condition in which lacks an effective medication.
